Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in RLAY.

← Back to Free Index

RLAY

Analysis as of: 2026-05-29

Relay Therapeutics, Inc.

Relay Therapeutics is a clinical-stage biotech developing precision medicines in cancer and genetic disease using a structure-and-motion-based discovery engine.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof First, Franchise Later

The upside is a clinical-franchise rerating, not a software multiple. Recent data and financing improved the path, but late-stage proof and regulatory alignment still determine whether the platform compounds or stalls.

Analysis

Thesis

Relay is a leveraged but credible bet that zovegalisib becomes a multi-indication PI3Kα franchise while its discovery engine improves follow-on hit rates; if late-stage proof holds, the story can rerate from single-asset biotech to emerging precision-medicine franchise by 2031.

Last Economy Alignment

AI helps Relay design molecules and compound proprietary data, but value capture still sits in owned assets, IP, and regulatory proof rather than software distribution. It benefits from cheaper cognition, yet biology and FDA gates remain the real bottlenecks.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.7x (from 5 most recent analyses)

Reasoning

The upside case is a real franchise, not a platform-software story. A successful second-line breast cancer path, credible frontline expansion, and a usable vascular-anomalies pillar can lift Relay into a materially larger revenue base by 2031. The recent financing lowers near-term fragility, but dilution and clinical concentration keep this in multi-bagger territory rather than extreme moonshot territory.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

Relay's core risk is concentrated proof. The discovery engine, IP, and cash matter, but the five-year outcome is still governed by whether zovegalisib keeps its efficacy and tolerability edge in larger studies, wins a workable regulatory path, and reaches market without per-share value being overly diluted.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On May 19, 2026, initial ReInspire vascular-anomalies data made the second commercial pillar more credible, though still early.
On May 20, 2026, Relay priced a 22.9 million share offering at 12.00 per share for roughly 275 million of gross proceeds, improving runway but adding dilution.
On May 27, 2026, management announced June 3 and June 8 conference appearances; near-term repricing is now more commentary-driven than data-driven.

Thesis update

The core thesis is unchanged, but it is now broader: zovegalisib looks less like a single-indication asset and more like a potential franchise if follow-up data hold.

Forecast update

The forward value case improved modestly because indication breadth looks more credible and the balance sheet is less fragile, partly offset by dilution.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.31

They use AI and structural biology to make drug candidates they own, so each clinical result can improve the next shot on goal. But they do not control a software standard, and one weak late-stage dataset can still overpower the learning flywheel.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$21.25

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research